Category: Biohaven Pharmaceuticals

  • Pfizer buys its way into migraine with $11.6B Biohaven Pharma acquisition

    Pfizer is turning to M&A to get its next blockbuster, buying Biohaven six months after the two companies began a commercialization pact centered on the oral migraine drug Nurtec. The acquisition will lead to the spinout of Biohaven’s other assets into a new, publicly traded company capitalized with $275 million.

  • Pfizer upgrades Biohaven alliance to a takeover bid

    Not content with a $1.2 billion licensing deal for Biohaven Pharma’s oral migraine therapy rimegepant, Pfizer has just offered to buy the company outright – for a cool $11.6 billion. Pfizer’s earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of […]

  • Pfizer/Biohaven migraine drug rimegepant gets EU green light

    Pfizer’s $1.2 billion licensing deal with Biohaven for rights to oral migraine drug rimegepant is approaching a payoff after the European Commission approved the drug. The regulator cleared the oral CGRP inhibitor as Vydura for both treatment and prevention of episodic migraine attacks, becoming the first drug to be authorised for both uses in the […]

  • AbbVie sees bigger role for Qulipta in migraine prevention

    AbbVie’s Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category currently dominated by injectable therapies. The phase 3 PROGRESS trial showed that taking Qulipta (atogepant) every day – ether in a once-daily […]

  • Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug

    Pfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights outside the US to Biohaven’s Nurtec ODT, an oral therapy for migraine. The agreement includes a sizeable $500 million upfront payment, reflecting that Nurtec ODT (rimegepant) is already FDA-approved for treating acute migraine with and without aura […]

  • Biohaven’s migraine progress pays off with a Pfizer marketing pact for two drugs

    Biohaven Pharmaceuticals has seen strong U.S. market uptake for its oral migraine drug, Nurtec. With regulatory decisions looming around the world, the company has landed the marketing muscle of Pfizer, which is paying $500 million up front for the right to market that drug and another clinical-stage compound outside of the U.S.

  • AbbVie’s Qulipta cleared for migraine prevention, setting up Biohaven clash

    AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. Qulipta (atogepant) is AbbVie’s second oral CGRP inhibitor after Ubrelvy (ubrogepant) – which was approved for the acute treatment of migraine attacks in 2019 – and rounds […]

  • Bad news for Biohaven as verdiperstat flunks first phase 3 test

    Biohaven’s key pipeline drug verdiperstat has failed to have any Therapeutic effect in patients with the rare neurological disorder multiple system atrophy (MSA) – its lead indication – but the biopharma company isn’t ready to abandon the drug yet. Myeloperoxidase (MPO) inhibitor verdiperstat was no better than placebo in the M-STAR trial in patients with […]